Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0001213900-25-088676·Camp4 Therapeutics Corp
Schedule 13G ownership disclosure
CAMP4 Therapeutics Corp.
Common Stock, par value $0.0001 per share · CUSIP: 13463J101
Event date: 2025-09-11
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Vivo Opportunity Fund Holdings, L.P.
Shares: 3,561,793.00 · Class: 7.6%
- Vivo Opportunity, LLC
Shares: 3,561,793.00 · Class: 7.6%
- Vivo Opportunity Cayman Fund, L.P.
Shares: 359,775.00 · Class: 0.8%
- Vivo Opportunity Cayman, LLC
Shares: 359,775.00 · Class: 0.8%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001213900-25-088676
- Form type
- SCHEDULE 13G
- Filer
- Camp4 Therapeutics Corp
- CIK
- CIK 1736730
- Filed
- Sep 17, 2025
- Reporting period
- Sep 11, 2025
- Description
- Schedule 13G beneficial ownership